The basal insulin analogue LY2605541 , a PEGylated insulin lispro with prolonged duration of action , was previously shown to be associated with modest weight loss in Phase 2 , randomized , open-label trials in type 2 ( N = 288 ) and type 1 ( N = 137 ) diabetes mellitus ( T2DM and T1DM ) , compared with modest weight gain with insulin glargine .